Akut iskemik inmede intravenöz trombolitik tedavi: Klinik değerlendirme

Amaç: İnme tedavisinde asıl amaç, oklüde vasküler yapının belirli süre içerisinde rekanalizasyonudur. Medikal tedavide rekombinant doku plazminojen aktivatörü (tPA) kullanılmaktadır. Bu çalışmada, tPA tedavisi verilen iskemik inme hastaları değerlendirilmiştir. Gereç ve Yöntem: Temmuz 2015-Ağustos 2017 arasında tPA tedavisi uygulanan 97 akut iskemik inme hastası retrospektif incelendi. Demografik veriler, başvuru semptomları ve tedavi saatleri kaydedildi. Klinik durum ve prognoz ‘National Institutes of Health Stroke Skalası’ (NIHSS) ve fonksiyonel durum ölçeği ile değerlendirildi. Hemorajik dönüşüm bilgisayarlı tomografi ile değerlendirildi. Bulgular: Çalışmaya 61(%62,8) erkek ve 36 (%37,2) kadın hasta alındı. Yaş ortalamaları 60,29±12,62 idi. 7 (%7,2) hastaya 1. saate, 5(%25,8) hastaya 1-2 saat arasında, 31(%32) hastaya 2-3 saat arasında, 34 (%35,1) hastaya 3-4,5 saat arasında tPAbaşlandı. Başvuruda en sık semptom hemi/monoparezi idi (%92,8).%69,1 oranında parsiyel anterior, %16,5 total anterior, %15,8 posterior vasküler oklüzyon saptandı. NIHSS sonuçları 10,39±4,36 (tedavi öncesi) ve 6,63±3,76 (taburculuk) idi. Hastalartam bağımsız (%20,6), kısmi bağımlı (%43,3) ve tam bağımlı (%21,6) olarak taburcu edildi.Hastaların %12’sinde hemorajik dönüşüm izlendi.Platelet değeri düşük olan hastalarda hemorajik transformasyon daha fazlaydı (P

Objective: The main purpose of treatment in stroke is recanalization of occluded vascular structure within a certain time period. Recombinant tissue plasminogen activator (tPA) is used for medical treatment. In this study, patients with ischemic stroke treated with tPA were evaluated. Material and Methods: Between July 2015 and August 2017, 97 patients with acute ischemic stroke who were treated with tPA reviewed retrospectively. Demographic data, presentation symptoms and treatment times were recorded. Clinical status and prognosis were evaluated with National Institutes of Health Stroke Scale (NIHSS) and functional status scale. Hemorrhagic transformation was evaluated with computed tomography. Results: 61 (62.8%) male and 36 (37.2%) female patients were included to study. The mean age was 60.29±12.62. tPA was started to 7 (7.2%) patients in 1 hour, 25 (25.8%) patients in 1-2 hours, 31 (32%) patients in 2-3 hours, 34 (35.1%) patients in 3-4.5 hours. The most common symptom was hemi/monoparesis (92.8%). 69.1% partial anterior, 16.5% total anterior and 15.8% posterior vascular occlusion were detected. NIHSS results were 10.39±4.36 (pre-treatment) and 6.63±3.76 (discharged). Patients were discharged with not disabilty (20.6%), partial disabilty (43.3%) and major disabilty (21.6%). Hemorrhagic transformation was detected in 12% of patients. Hemorrhagic transformation was higher in patients with low platelets (P

___

1. Blackham KA, Meyers PM, Abruzzo TA, et al. Endovasculartherapy of acuteischemicstroke: report of thestandards of practicecommittee of thesociety of neurointerventionalsurgey. J Neurointerv Surg 2012;4:87-93.

2. Kumral E, Balkır K. İnme epidemiyolojisi. In: Balkan S, ed. Serebrovasküler hastalıklar. 1. baskı, Ankara: Güneş Kitapevi, 2002;38-40.

3. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heartdiseaseandstroke statistics-2017 update: a reportfromthe American Heart Association. Circulation 2017;135:146-603.

4. Heiss WD. Theischemic penumbra: correlates in imaging andimplications for treatment of ischemicstroke. Cerebrovasc Dis 2011;32:307-20.

5. Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysiswithalteplase for acuteischaemicstroke in theSafeImplementation of Thrombolysis in Stroke-MonitoringStudy (SITS-MOST): an observationalstudy. The Lancet 2007;369:275-82.

6. Hacke W, Kaste M, Fieschi C, et al. Intravenoustrombolysiswithrecombinanttissueplasminogenactivator for acutehemisphericstroke. JAMA 1995;274:1017-59.

7. Katzan IL, Hammer MD, Hixson ED, et al. Utilization of intravenoustissueplasminogenactivator for acuteischemicstroke. Arch Neurol 2004;61:346-50.

8. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysiswithalteplase 3 to 4.5 hoursafteracuteischemicstroke. N Engl J Med 2008;359:1317-29.

9. Kanazawa M, Takahashi T, Nishizawa M, Shimohata T. Therapeutic strategies to attenuate hemorrhagic transformation after tissue plasminogen activator treatment for acute ischemic stroke. J AtherosclerThromb 2017;24:240-53.

10. Zhang Y, Yang H, Sun Y, Xing Y. Hemorrhagic transformation after cerebral infarction: current concepts and challenges. Ann Transl Med 2014;2:81-8.

11. Sadeghi-Hokmabadi E, Farhoudi M, Taheraghdam A, et al. Intravenous recombinant tissue plasminogen activator for acute ischemic stroke: a feasibility and safety study. Int J Gen Med 2016;9:361-7.

12. Guo Y, Yang Y, Zhou M, He L. Risk factors of haemorrhagic transformation for acute ischaemic stroke in Chinese patients receiving intravenous recombinant tissue plasminogen activator: a systematic review and meta-analysis. Stroke VascNeurol2018;3:203-8.

13. Saver JL, Fonarow GC, Smith EE, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA 2013;309:2480-8.

14. Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, vanGijn J. Inter observer agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-7.

15. National Institute of Neurological Disordersand Stroke rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.

16. Wardlaw J, Berge E, Zoppo G, Yamaguchi T. Thrombolysis for acut ischemic stroke. Stroke 2004;35:2914-5.

17. Wardlaw JM, Warlow CP. Thrombolysis in acute ischemic stroke: Does it work?. Stroke 1992;23:1826-39.

18. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischemic stroke in the safe implementation of thrombolysis in stroke monitoring study: an observational study. Lancet 2007;369:275-82.

19. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooledanalysis of ATLANTIS, ECASS, and NINDS rt-PA stroketrials. Lancet 2004;363:768-74.

20. Saver JL. Number needed to treat estimates in corporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acutes troke. ArchNeurol 2004;61:1066-70.

21. Saqqur M, Uchino K, Demchuk AM, et al. Site of arterial occlusion identified by transcranial doppler predicts the response to intravenous thrombolysis for stroke. Stroke 2007;38:948-54.

22. Kim DH, Lee DS, Nah HW, Cha JK. Clinicaland radiological factors associated with unfavorable outcome after intravenous thrombolysis in patients with mild ischemic stroke. BMC Neurol 2018;18:30.

23. Marti-Fabregas J, Bravo Y, Cocho D, et al. Frequency and predictors of symptomatic intracerebralhemorrhage in patients with ischemic stroke treated with recombinant tissue plasminogen activator outside clinical trials. CerebrovascDis 2007;23:85-90.

24. Yaghi S, Boehme AK, Dibu J, et al. Treatment and outcome of thrombolysis-related hemorrhage: A multicenter retrospective study. JAMA Neurol 2015;72:1451-7.

25. Sadeghi-Hokmabadi E, Farhoudi M, Taheraghdam A, et al. Intravenous recombinant tissue plasminogen activator for acute ischemic stroke: a feasibility and safety study. Int J Gen Med 2016;9:361-7.
Genel Tıp Dergisi-Cover
  • ISSN: 2602-3741
  • Yayın Aralığı: Yılda 6 Sayı
  • Başlangıç: 1997
  • Yayıncı: SELÇUK ÜNİVERSİTESİ > TIP FAKÜLTESİ
Sayıdaki Diğer Makaleler

Çocukluk çağı karsinoid tümörleri : Tek merkez deneyimi

Buket KARA, METİN GÜNDÜZ, HASAN MADENCİ, YAVUZ KÖKSAL

Boy kısalığı olan çocukların serum ürotensin 2 düzeylerinin igf-1 ile ilişkisi

Muhammed YAYLA, Damla ÇETİN, SEFER ÜSTEBAY, Hayrunisa BEKİS BOZKURT, Ömer ERTEKİN, Döndü Ülker ÜSTEBAY

Akut iskemik inmede intravenöz trombolitik tedavi: Klinik değerlendirme

Fettah EREN, Gözde ÖNGÜN, Aydın Talip YILDOĞAN, Melike IŞIK, Şerefnur ÖZTÜRK

Ameliyathane hemşirelerinde iş doyumu ve mesleki profesyonellik

KEMAL MACİT HİSAR, Ali OFLAZ

Koroner arter çıkış varyasyonlarının çok kesitli bilgisayarlı tomografi (ÇKBT) ile değerlendirilmesi

FADİME GÜVEN, Mecit KANTARCI

Tıp fakültesi internlerinin tıp eğitimi ile tıpta uzmanlık sınavı hakkındaki düşünceleri ve branş tercihlerinin belirlenmesi

Duygu İlke YILDIRIM, Kamile MARAKOĞLU

Parotis bezi tümörü nedeniyle ameliyat edilen olgularımızın retrospektif analizi

İsa ÖZBAY, MUHAMMET FATİH TOPUZ, Cüneyt KUCUR, FATİH OĞHAN, Aykut CEYHAN, Hüseyin METİNEREN

Erkek hipogonadotropik hipogonadizm tanılı hastaların fertilizasyon oranlarının belirlenmesi ve fertilizasyonu etkileyen faktörlerin değerlendirilmesi

Ferhat BACAKSIZ, FARUK KILINÇ, ZAFER PEKKOLAY, ALPASLAN KEMAL TUZCU

MR ile saptanan uterus didelphys bicollis olgusu

Ayşe Gamze ÖZCAN, Nadire ÜNVER DOĞAN, Ahmet BAYTOK, Zeliha FAZLIOĞULLARI

Sjögren sendromu ve granülomatöz polianjiitis birlikteliği gösteren bir olgu

Dilek TEZCAN, Muhammet LİMON, Semral GÜLCEMAL, Sema YILMAZ